P
USRE46152EExpiredUtilityPatentIndex 43

Dendritic cell compositions and methods

Assignee: ARGOS THERAPEUTICS INCPriority: Apr 8, 2005Filed: Apr 7, 2006Granted: Sep 20, 2016
Est. expiryApr 8, 2025(expired)· nominal 20-yr term from priority
Inventors:POGUE REBECCAMONESMITH TAMARATCHEREPANOVA IRINADINTERMAN LOIS
A61P 31/00C12N 2501/2304A61P 31/18C12N 2506/115C12N 2501/24A61P 35/02A61P 31/16C12N 2501/2306C12N 2523/00A61P 37/04C12N 2501/02A61P 31/04C12N 2501/25C12N 2506/11A61P 35/00C12N 2501/23A61P 37/00C12N 2501/22A61P 31/14C12N 2501/2301A61P 31/12C12N 2502/11A61K 40/19A61K 2039/5154C12N 5/0639A61K 2300/00A61K 2121/00A61K 39/0011
43
PatentIndex Score
0
Cited by
43
References
21
Claims

Abstract

Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1° C.-34° C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method for producing dendritic cells from monocytes, comprising:
 a) providing enriching monocytes from a leukapheresis product by elutriation, wherein prior to elutriation, monocytes that have been incubated without culturing at a temperature maintained between 1° C.-34° C. 1° C.-14° C. for a period of approximately 6 to 96 hours from following the time they are isolated the leukapheresis product is collected from a subject; and 
 b) inducing the differentiation of said monocytes into dendritic cells. 
 
     
     
       2. The method of  claim 1 , wherein the monocytes are human monocytes. 
     
     
       3. The method of  claim 1 , wherein the incubation temperature is maintained between 6° C.-28° C about 6° C.-8° C. 
     
     
       4. The method of  claim 1 , wherein the incubation temperature is maintained between 8° C.-26° C 1° C.-8° C. 
     
     
       5. The method of  claim 1 , wherein the period of incubation is 8 to 48 hours. 
     
     
       6. The method of  claim 5 , wherein the period of incubation is 10 to 30 hours. 
     
     
       7. The method of  claim 1 , wherein the period of incubation is 26 to 72 hours. 
     
     
       8. The method of  claim 1 , wherein the period of incubation is 48 to 80 hours. 
     
     
       9. The method of  claim 1 , wherein the differentiation is induced by contacting the monocytes in a culture medium comprising an effective amount of a composition that induces the differentiation of monocytes into immature dendritic cells. 
     
     
       10. The method of  claim 1 , wherein the monocytes are present together with peripheral blood mononuclear cells (PBMCs) during all or a portion of the incubation period. 
     
     
       11. The method of  claim 10 , wherein the PBMCs are isolated from the subject by leukapheresis. 
     
     
       12. The method of  claim 10 , wherein the monocytes are enriched from the PBMCs during or following the incubation period. 
     
     
       13. The method of  claim 9 , further comprising a step of maturing the immature dendritic cells into mature dendritic cells. 
     
     
       14. The method of  claim 13 , further comprising loading one or more antigens into said mature dendritic cells. 
     
     
       15. The method of  claim 1 , wherein the incubation temperature is between 1° C.-20° C about 6° C.-14° C. 
     
     
       16. The method of claim  12  1, further comprising the step of freezing said enriched monocytes. 
     
     
       17. The method of claim 1, wherein the period of incubation is 26 to 96 hours. 
     
     
       18. The method of claim 1, wherein said monocytes are subjected to occasional or continuous motion during the incubation period. 
     
     
       19. The method of any one of claims 1 to 9, 13 to 16, and 17, wherein said monocytes are subjected to occasional or continuous motion associated with shipping during the incubation period. 
     
     
       20. The method of claim 18, wherein said motion is associated with shipping. 
     
     
       21. The method of claim 18, wherein said motion may prevent cell damage associated with compaction during settling.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.